በTexas ለክሮኒክ ማይሎሞኖሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ማይሎሞኖሳይቲክ ሉኬሚያ የሚደረጉ 18 ጥናቶች በTexas ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በTexas ውስጥ ያሉ ከተሞች

Houston16 ጥናቶች

Official study text (English)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

The University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT04996875

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03683433

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06566742

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT03383575

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT07033598

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

AIR Care, Dallas

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT07143669

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2/3ጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT04708054

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05092451

Personalized NK Cell Therapy in CBT

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ ከ15 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁላይ 2026 · NCT02727803

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

The University of Texas M. D. Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁላይ 2026 · NCT07128381

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT04239157

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT03896269

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

University of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2/3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT04140487

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

MD Anderson, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ማርች 2026 · NCT06994676

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT06950034

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

MD Anderson Cancer Center, Huston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2025 · NCT03850574

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።